Table 4

Analysis of the G-CSF preference for primary and secondary prophylaxis according to healthcare sector in which the physicians work

G-CSF attribute	Primary prophylaxis preference				Secondary prophylaxis preference (exploratory analysis)
	Public sector (n=150)		Private sector (exclusively or with public sector) (n=55)		Public sector (n=150)		Private sector (exclusively or with public sector) (n=55)
	Coefficient	P value	Coefficient	P value	Coefficient	P value	Coefficient	P value
Efficacy
Risk of febrile neutropenia with prophylaxis	0.038	0.042
G-CSF characteristic
Biosimilar	0.148	<0.001	0.135	<0.001	0.121	<0.001
G-CSF administration and cost
Cost per injection, including cost of nurse (euros)	0.11×	<0.001	0.125	<0.001	0.098	<0.001	0.114	<0.001
Number of injections per chemotherapy cycle	0.213	<0.001	0.208	<0.001	0.147	<0.001	0.096	<0.001
Tolerance
Pain at the injection site	0.072	<0.001	0.091	0.004			0.082	0.012
Bone pain present	−0.04	0.034			−0.072	<0.001	−0.073	0.025
Fever/influenza syndrome present					−0.04×	0.041	−0.082	0.012